drugset / Trial / NCT06110208
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML
Phase 0
Terminated
3 enrolled
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Gracell Biotechnologies (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population were patients with relapsed and refractory acute myeloid leukemia (r/r AML) .
Timeline
- Start
- 2023-10-10
- Primary completion
- 2024-07-01
- Completion
- 2024-07-01
Outcome
Outcome not reported
Stopped: “Collaborator's decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Cell therapy | — | — |